Arvinas (Nasdaq: ARVN) will host a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET to review its second quarter 2026 financial results and provide a corporate update. The event will be accessible via the “Events and Presentations” section on the Arvinas investor webpage, with a replay available afterward.
Arvinas is a biotechnology company focused on targeted protein degradation through its PROTAC protein degrader platform. The company, which co-developed the first FDA‑approved PROTAC with Pfizer, is advancing multiple investigational drugs for neurodegenerative disorders, mutated cancers, relapsed/refractory non-Hodgkin lymphoma, and skeletal muscle conditions.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ARVN
-0.24%
2 alerts
-0.24%Session close to close
-15.1%Trough Tracked
$564.12MMarket Cap
0.6xRel. Volume
In the Jul 28 session, ARVN declined 0.24%, reflecting a mild negative market reaction.
Argus tracked a trough of -15.1% from its starting point during tracking.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
ARVN's two prior earnings-date notices were followed by -1.58% and -1.80% 24-hour reactions. That hi...
Analysis
ARVN's two prior earnings-date notices were followed by -1.58% and -1.80% 24-hour reactions. That historical backdrop frames this scheduling item; recent insider activity was net selling, while short positioning was categorized as low.
Key Figures
Reporting date:August 4, 2026Webcast time:8:00 a.m. ET
Prior scheduling notice preceded a negative 24-hour reaction of -1.80%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Both tag-matched earnings-date notices were followed by negative 24-hour reactions: -1.58% and -1.80%.
Key Terms
protac, targeted protein degradation, heterobifunctional protein degrader, fda
4 terms
protactechnical
"Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform"
A PROTAC (proteolysis targeting chimera) is a small engineered molecule that tags a specific protein inside cells and brings it to the cell’s disposal machinery so the protein is destroyed rather than just blocked. Think of it as a targeted cleanup crew that removes a problematic part instead of temporarily turning it off. Investors care because PROTACs can tackle disease targets that traditional drugs cannot, creating potential for breakthrough therapies, larger markets, and binary clinical readouts that can sharply affect company value.
targeted protein degradationtechnical
"creating a new class of drugs based on targeted protein degradation"
Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.
heterobifunctional protein degradertechnical
"a type of heterobifunctional protein degrader"
A heterobifunctional protein degrader is a designed molecule with two linked ends: one binds a specific target protein and the other recruits the cell’s protein-removal machinery, forcing the cell to tag and destroy the target. Think of it as a molecular bridge that brings a marked item to the cell’s trash system. It matters to investors because it represents a therapeutic approach that can remove disease-related proteins and can expand drug pipelines and valuation prospects for biotech companies.
fdaregulatory
"the first U.S. Food and Drug Administration (FDA) approved PROTAC"
The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA) approved PROTAC, a type of heterobifunctional protein degrader.
Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
When will Arvinas (NASDAQ: ARVN) report its Q2 2026 financial results?
Arvinas will review its second quarter 2026 financial results on August 4, 2026 at 8:00 a.m. ET. According to Arvinas, management will also provide a corporate update during a live webcast accessible through its investor relations webpage.
How can investors access the Arvinas (ARVN) Q2 2026 earnings webcast?
Investors can access the Arvinas Q2 2026 webcast under “Events and Presentations” on the company’s investor page. According to Arvinas, a replay will be available on its website after the event’s completion for later viewing.
What will Arvinas cover during the August 4, 2026 ARVN webcast?
Arvinas plans to review its second quarter 2026 financial results and provide a corporate update. According to Arvinas, company management will host the live webcast and discuss current activities and progress across its targeted protein degradation programs.
What does Arvinas (NASDAQ: ARVN) do in targeted protein degradation?
Arvinas develops drugs using its PROTAC protein degrader platform to remove disease-causing proteins. According to Arvinas, this approach harnesses the body’s natural protein disposal system to selectively degrade target proteins in debilitating and life-threatening diseases.
Which clinical programs is Arvinas (ARVN) currently advancing?
Arvinas is progressing multiple investigational drugs, including ARV-102, ARV-806, ARV-393, and ARV-027. According to Arvinas, these candidates target LRRK2, KRAS G12D, BCL6, and polyQ-AR in neurodegenerative disorders, mutated cancers, relapsed/refractory non-Hodgkin lymphoma, and skeletal muscle disease.
What is the relationship between Arvinas and Pfizer mentioned by ARVN?
Arvinas and Pfizer co-developed the first FDA-approved PROTAC, a heterobifunctional protein degrader. According to Arvinas, this collaboration helped bring the first approved targeted protein degradation therapy to the U.S. market, validating its PROTAC platform approach.
Where is Arvinas (ARVN) headquartered and how can investors get more information?
Arvinas is headquartered in New Haven, Connecticut, and provides information on its website at www.arvinas.com. According to Arvinas, investors can also follow updates via the company’s LinkedIn and X social media channels for additional corporate and pipeline news.
